Ela¢n (also known as skin-derived anti-leukoproteinase/trappin-2) is an epithelial host-defense protein that is absent in normal skin but highly induced in keratinocytes of in£amed skin (e.g., psoriasis), in epidermal skin tumors, and after wounding. Previously, it was shown that in cultured keratinocytes, ela¢n expression is induced by serum or tumor necrosis factor^a, and that expression is suppressed by retinoids, dithranol, and p38 mitogen-activated protein kinase inhibitors. Here we have studied the regulation of ela¢n gene expression in epidermal keratinocytes at the molecular level. First we determined the transcription start site of the ela¢n gene and found that the ela¢n mRNA possesses an unusually short 5 0 -untranslated region. Using transient transfection of luciferase reporter constructs of the ela¢n promoter, we mapped a 440 bp region upstream of the translation start site that conferred high-level expression in keratinocytes, but not in A431 cells or cells of mesenchymal origin. We observed that the promoter constructs were not subjected to the same regulation as the endogenous ela¢n gene as these constructs were highly active independent of keratinocyte stimulation. When ela¢n promoter constructs were stably transfected in the HaCaT keratinocyte cell line, tumor necrosis factor-a inducible expression of both the endogenous ela¢n gene and the transgene was observed, suggesting that regulation of the ela¢n gene is also dependent on chromatin structure. We found, however, that a stably transfected 4 kb ela¢n promoter fragment did not confer retinoid sensitivity indicating that additional sequences are required for proper regulation. This study reveals the complex regulation of a gene that can be used as a paradigm for the speci¢c di¡erentiation program of activated epidermal keratinocytes.
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A number of genes have been described previously, whose expression is induced or highly upregulated under the conditions mentioned above. Well-known examples are the hyperproliferation-associated cytokeratins CK 6, 16, and 17 . Similar to the expression of CK 6, 16, and 17 (Navarro et al, 1995) , the expression of the gene encoding ela¢n (also known as skin-derived anti-leukoproteinase) is tightly correlated with abnormal epithelial di¡erentiation in a context of hyperproliferation. Ela¢n is highly expressed in keratinocytes of psoriatic epidermis (Wiedow et al, 1990; Schalkwijk et al, 1993) and is inducible in vivo by ultraviolet B irradiation (Pfundt et al, 2001) , and by tape stripping (a standardized model for epidermal injury and transepidermal water loss) (Alkemade et al, 1992; Gerritsen et al, 1994) .
By extrapolation, we hypothesize that knowledge on the molecular regulation of ela¢n expression could provide information on the molecular regulation of the phenotype associated with activated epidermis and its characteristic program of gene expression. In previous studies it has been shown that ela¢n gene expression can be induced in vitro by stimulation of cultured undi¡erentiated primary keratinocytes with either fetal bovine serum (FBS) or tumor necrosis factor (TNF)-a (Pfundt et al, 1996 (Pfundt et al, , 2000 van Ruissen et al, 1996) . This in vitro induction of ela¢n was shown to be dependent on the activity of the mitogen-activated protein kinase family member p38. In addition we showed that ela¢n expression in vivo is induced by ultraviolet B irradiation of normal human skin, is also correlated with p38 activation (Pfundt et al, 2001) . This led to the hypothesis that the expression of ela¢n is part of an epidermal stress response that is possibly deregulated in pathologic skin conditions such as psoriasis. Interestingly, ela¢n expression was found to be downregulated by retinoids and by dithranol, which are known potent anti-psoriatics (Nagpal et al, 1996; Pol et al, 2002a) . We therefore regard ela¢n expression as a surrogate marker for psoriasis.
So far, regulation of ela¢n gene expression at the molecular level has only been studied in nonkeratinocyte cells such as breast epithelial and lung epithelial cell lines (Zhang et al, 1997; Bingle et al, 2001 ). These studies, using transient transfections, have revealed that transcription factor binding sites for alkaline phosphatase-1 and nuclear factor (NF) kB in the ela¢n promoter are important. Ela¢n expression and function in keratinocytes has been studied in detail at the cellular level in vivo, but knowledge of its molecular regulation is lacking. We have studied regulation of the ela¢n gene in primary epidermal keratinocytes and in the HaCaT keratinocyte cell line. An important observation from our studies is that, at least in keratinocytes, ela¢n promoter activity cannot be simply inferred from transient transfection studies, suggesting that other crucial regulatory mechanisms exist.
MATERIALS AND METHODS
Chemicals All chemicals were obtained from Merck (Darmstadt, Germany) with the exception of TNF-a (Boehringer, Mannheim, Germany) and all-trans retinoic acid (RA) (Sigma, St Louis, MO). A 5 mM stock solution of RA was prepared in ethanol. Restriction enzymes were from Boehringer. Primers were from Isogen (Amsterdam, the Netherlands).
Cloning of the human ela¢n gene promoter region and reporter gene constructs We have previously reported the cloning of a 9 kb HindIII genomic fragment in pBluescript (Stratagene, La Jolla, CA), which was shown to contain the human ela¢n gene (Molhuizen et al, 1994) . This clone was designated pSKAG. From this clone an EcoRI/XbaI fragment containing approximately 1 kb promoter region in addition to a small part of the ¢rst exon was cloned in pBluescript KS þ resulting in clone pSPRO29. Construct pSPRO29 was used as template in a PCR reaction synthesizing the 1 kb promoter fragment (position^1012/ þ 13; all nucleotide positions in this paper are given relative to the start site of translation; see Fig 1) . Two primers [forward: 5 0 -GAATTCCCGGG TTCATATAT-3 0 , position^1012/^993 (mutated nucleotide is underlined), reverse: 5 0 -TGCTGGCCCCCATGGTGTCA, position À7/ þ 13) were used to introduce a SmaI site and a NcoI at the 5 0 and the 3 0 site of the polymerase chain reaction (PCR) product, respectively. The PCR product was cloned in the pGEM-4 T-vector (Promega, Madison, WI) and sequenced for veri¢cation. From this clone a 1 kb SmaI/NcoI fragment (position À1004/ þ 3) was directionally subcloned in frame with the ¢re£y luciferase gene in pSla4, a modi¢ed pSla3 vector (van Dijk et al, 1991) , directly fused to the ATG of the luciferase gene through the NcoI site. The resulting clone was designated pSPL1000. From this clone deletion mutants were derived and designated pSPL440, pSPL290, pSPL170, and pSPL130. All these constructs were prepared according to standard cloning techniques using available restriction sites, except clone pSPL130. To generate this clone we used a mutagenic forward primer (5 0 -GTGGATATCTCCCAATAC-3 0 , position À132/À115) in a PCR reaction with the previously mentioned reverse primer to introduce an EcoRV site at position À126. From the resulting PCR product an EcoRV/NcoI fragment was cloned in a SmaI/NcoI digested pSLA4 vector. The largest transfection construct pSPL4500 was constructed via directional cloning of an approximately 4 kb HindIII/BglII promoter fragment (position À4500/À435) in a SmaI/BglII digested pSPL1000 construct. The two promoter constructs pSPL1000int þ and pSPL1000int À contain the entire genomic sequence of the ela¢n gene in the correct and reverse orientation, respectively. Both constructs containing the genomic ela¢n sequence were made by directional cloning of a PCR product containing the entire gene sequence (position þ 3/ þ 1631) in the KpnI site of construct pSPL1000 between the stop codon and the ¢rst polyadenylation signal of the luciferase gene. Finally, a construct containing the insert from clone pSPL1000 in the reverse orientation, designated pSPL1000rev was generated. To obtain this clone, the previously mentioned 1 kb SmaI/NcoI fragment was used. A blunt end was generated at the NcoI site, and the complete fragment was subcloned in the SmaI site from pSla4, thus maintaining the original translation start codon from the luciferase gene. Figure 2 (A) gives a schematic representation of these nine constructs.
Determination of the ela¢n mRNA transcription start site using S1-nuclease mapping S1 nuclease mapping using a single-stranded DNA probe was used to determine the start site of transcription of the ela¢n gene. To obtain a suitable DNA probe we cloned a BglII/XbaI fragment (position À435 to þ 62) in pBluescript KS þ . Single-stranded DNA was obtained by transforming the plasmid in Escherichia coli XL1-Blue cells and infecting the transformed cells with M13K07 helper phage (as described in Sambrook et al, 1989) . To prepare the radiolabeled probe, T7 primer (Promega) was annealed to 250 ng single-stranded DNA, and primer extension was performed with 5 U of T7 DNA polymerase (Pharmacia, Uppsala, Sweden) in the presence of 0.5 mM [a-32 P]deoxycytidine triphosphate (3000 Ci per mmol; Amersham, Buckinghamshire, U.K.), 0.4 mM deoxyadenosine triphosphate, 0.4 mM deoxythymidine triphosphate, 0.4 mM deoxyguanosine triphosphate, and 1.3 mM deoxycytidine triphosphate (Amersham Biosciences, Uppsala, Sweden). The radiolabeled fragment was separated from the template on a 4% polyacrylamide gel and isolated. Total RNA isolated from keratinocytes grown in the presence of 5% FBS was used as a source for ela¢n mRNA. Fifty micrograms of this total RNA was mixed with 8 Â 10 5 cpm single-stranded probe DNA. As a negative control yeast tRNA (Boehringer) was used. The pellets were dissolved in 30 ml hybridization bu¡er [40 mM PIPES (piperazine-N,N,-bis[2-ethanesulfonic acid]) pH 8.0, 0.5 M NaCl, and 80% formamide] and incubated for 10 min at 851C followed by an incubation for 16 h at 501C. After this probe hybridization, 300 ml nuclease S1 reaction mix (280 mM NaCl, 5 mM NaAc pH 4.5, 4.5 mM ZnSO 4 , 20 mg herring sperm DNA per ml (Boehringer) and 1000 U per ml nuclease S1 (Amersham Biosciences) was added and the reaction was incubated at 371C for 60 min. As a control reaction to check for su⁄cient nuclease S1 activity, free radiolabeled probe was subjected to nuclease S1 digestion. The samples were separated on an 8% polyacrylamide gel, and autoradiography was performed using Kodak X-Omat 100 X-ray ¢lm.
Determination of ela¢n mRNA transcription start site using 5 0 -RACE (rapid ampli¢cation of cDNA ends) RACE was used to recon¢rm transcription start sites of endogenous ela¢n found with S1-nuclease mapping in human keratinocytes. Using the 5 0 /3 0 -RACE kit (Boehringer) we performed 5 0 -RACE on 10 mg of total RNA isolated from keratinocytes grown in keratinocyte growth medium (KGM)/FBS, as suggested by the manufacturer. In the RACE reaction the ela¢n speci¢c primers (SP) used were the primers SP1 ( þ 1013/ þ 1037), SP2 ( þ 942/ þ 966), and SP3 ( þ 30/ þ 48). The produced RACE fragment was puri¢ed on an agarose gel and cloned into the pGEM-T vector (Promega). The RACE clones obtained were sequenced by means of the dideoxy chain termination method.
Cell culture Normal human keratinocytes were seeded in six well culture dishes and cultured until con£uence in KGM as described before (van Ruissen et al, 1994) . At con£uence the cells were either transfected or switched to one of the test media. Subsequently, the growth factors or cytokines that were to be tested were added in di¡erent concentrations. Induction of keratinocyte di¡erentiation was established by switching the cells at con£uence either to KGM supplemented with 5% v/v FBS (KGM/ FBS) (FBS from Seralab, Nistelrode, the Netherlands) or to KGM depleted of growth factors (Bovine Pituitary Extract, insulin, and epidermal growth factor) and hydrocortisone (depleted of growth factors and hydrocortisone). Human skin ¢broblasts derived from healthy volunteers, glioblastoma cells, and A431 cells were seeded and cultured in six well culture dishes in A1 medium [Dulbecco minimal Eagle's medium (DMEM)/F12] (Flow Laboratories, Irvine, Scotland, U.K.) in a ratio of 3 : 1 supplemented with 100 U per ml penicillin, 100 mg streptomycin per ml and 10% v/v (FBS).
Transient transfections Keratinocytes were transfected at con£uence. Prior to transfection the cells were washed twice with 1 ml Keratinocyte Basal Medium and 900 ml Keratinocyte Basal Medium was added. Transfection mixes were made containing 0.75 pmol transfection construct 0.5 pmol EF2-bGAL normalization construct (a kind gift from Dr G. Swart, Department of Biochemistry, University of Nijmegen) and 25 ml lipidfection reagent (lipidfection reagent consisted of 0.8 mM dimethyldioctadecylammonium bromide (Sigma), and 1.7 mM dioleoyl-L-aphosphatidylethanolamine (Sigma), prepared according to a method described elsewhere (Carrol, 1994) , in a ¢nal volume of 100 ml Keratinocyte Basal Medium. These mixes were incubated for 20 min at room temperature and the cells were transfected during 6 h. Twenty-four hours after transfection the medium was aspirated and the cells were switched either to KGM/FBS or to depleted of growth factors and hydrocortisone, and incubated for another 24 h after which the cells were harvested.
The human ¢broblasts, glioblastoma cells, and A431 cells were transfected at 50^70% con£uence. Prior to transfection the cells were washed twice with 1 ml DMEM/F12 (ratio 3:1) and 900 ml DMEM/F12 was added. Transfection mixes were made containing 1.3 pmol transfection construct, 0.5 pmol EF2-bGAL and 25 ml DOSPER (Boehringer) in a ¢nal volume of 100 ml DMEM/F12. These mixes were incubated for 20 min at room temperature and added drop wise to the cells. After 6 h of incubation 1 ml A1 medium was added to the cells. Twenty-four hours after transfection the medium was aspirated and 2 ml A1 was added. After a ¢nal incubation of 24 h the cells were harvested.
Cell harvesting and reporter assays Transfected cells were washed twice with phosphate-bu¡ered saline (NPBI, Emmer-Compascuum, the Netherlands) and lyzed in 150 ml reporter lysis bu¡er (Promega). Luciferase enzyme assay was performed with the Luciferase Assay System (Promega) as suggested by the manufacturer using 10 ml cell lysate and 50 ml assay reagent. b-galactosidase enzyme assay was performed with the ''Galacto-Light Plus'' chemiluminescent reporter assay for the detection of b-galactosidase (Tropix Inc., Bedford, MA) as suggested by the manufacturer using 20 ml cell lysate. Promoter activities were measured as the ratio between the luciferase activity and b-galactosidase activity per sample.
Cell cultures of stably transfected HaCaT keratinocytes Previously, we have generated two stably transfected keratinocyte cell lines (HaCaT) in which, respectively, a 4 kb and a 0.8 kb fragment, derived from the promoter of the ela¢n gene, drive the transcription of a gene fusion of ela¢n and enhanced green £uorescent protein (EGFP) (Pol et al, 2002b) . The original clones designated ''clone VI B3'' and ''clone 21'' will hereinafter be referred to as 4 kb ela¢nprom and 0.8 kb ela¢nprom. Cells of these stable transfectants were seeded on to irradiated mouse 3T3 ¢broblast feeder layers in 24 -well tissue culture plates (Corning Costar, Badhoevedorp, the Netherlands). Cultures were grown in DMEM with 4.5 g per liter glucose with L-glutamine (BioWhittaker Europe, Verviers, Belgium) supplemented with 10% FBS (Harlan Seralab, Nistelrode, the Netherlands) and penicillin (100 U per ml)/streptomycin (100 mg per ml) (Life Technologies B. V., Breda, the Netherlands). Upon con£uence, cultures were switched to medium with or without 25 ng TNF-a per ml. Simultaneously, RA was added to the medium to create a dose range of 10
À6
, 10
À7
, and 10 À8 M and cultures were maintained for another 72 h. Culture supernatants were then collected and stored at À201C for later analysis in enzyme-linked immunosorbent assay. Total RNA was isolated and stored at À801C for northern blot analysis.
Northern blot analysis Total RNA was isolated from RA-treated cultures of HaCaT clones 4 kb ela¢nprom and 0.8 kb ela¢nprom, 72 h after con£uent cultures were switched to medium with or without TNFa. For isolation of total RNA we used TRIzol reagent according to directions of the manufacturer (Life Technologies B. V.). Samples were spectrophotometrically quantitated and equal amounts of 10 mg were separated on an agarose gel. The samples were blotted on positively charged nylon and subsequently used in hybridization experiments. The ela¢n probe was obtained by generation of a 0.42 kb PvuII/EcoRI fragment of the ela¢n cDNA clone pGESKA. The EGFP probe consisted of a 0.76 kb NotI/PstI fragment of pEGFP-N1. Probes were 32 P-labeled using an oligo labeling kit (Amersham Biosciences). Autoradiography was performed using Kodak X-OMAT X-ray ¢lms.
Analysis of secreted endogenous ela¢n Ela¢n levels were determined in medium derived from HaCaT cultures by means of a sandwich-type enzyme-linked immunosorbent assay, which is described elsewhere (Vandermeeren et al, 2001 ). An ela¢n calibration curve (0.5^12.5 ng per ml) was prepared from a stock of full-length ela¢n obtained by puri¢cation from cell culture supernatants. Concentrations of ela¢n were read from this curve and expressed as ng secreted ela¢n per ml culture medium.
Analysis of secreted ela¢n^EGFP fusion protein Ela¢n^EGFP fusion protein concentrations were measured in medium derived from HaCaT cultures using a sandwich-type enzyme-linked immunosorbent assay as previously described (Pol et al, 2002b) . Absorbance values for untransfected HaCaT served as background level. Levels of ela¢n^EGFP were expressed semiquantitatively as fold background.
RESULTS
The human ela¢n gene contains multiple transcription start sites and the mRNA has an unusually short 5 0 -untranslated region (5 0 -UTR) The cloning and partial structural characterization of the ela¢n gene and cDNA has been described previously (Saheki et al, 1992; Molhuizen et al, 1993 Molhuizen et al, , 1994 . Based upon the presence of consensus sequences for a TATA and CCAAT box, the region directly 5 0 of the translation start site was assigned as the putative promoter in previous studies by others, although this has not been veri¢ed experimentally. We initially used the S1-nuclease mapping technique to determine the transcription start site of the ela¢n gene. Using this technique, multiple transcription start sites were found from 9 to 24 bp upstream of the translation start site of the ela¢n gene (not shown). As these positions would result in an unusually short 5 0 -UTR, an independent method was used to con¢rm this region as being the region where ela¢n transcription can start. Application of the 5 0 -RACE technique also yielded short 5 0 fragments and con¢rmed the presence of multiple transcription start sites; however, less size variation was found, as 60% of all RACE clones were located around base residues À16/À17/À18 (Fig 3) .
Deletion mapping of the ela¢n promoter In order to scan the ela¢n promoter for sequences relevant for transcriptional activity in human keratinocytes, a set of nine reporter constructs (see Fig 2A) was designed covering approximately 4500 bp of upstream and approximately 1600 bp of downstream gene sequences. These constructs were transiently transfected in human keratinocytes that were stimulated with FBS (see Fig  2B) . Stepwise deletion of the region between À4500 and À440 did not a¡ect ela¢n promoter activity, as can be seen by the relative luciferase activity of the transfection clones pSPL4500, pSPL1000, and pSPL440. Based on the relative luciferase activity of the transfection clones pSPL1000int þ and pSPL1000int À , containing the intron sequences of the ela¢n gene in both orientations, it appears that the intron sequences do not have any e¡ect on promoter activity in either orientation. Subsequent deletion, however, of the region À440 and À290 (clone pSPL290) resulted in a signi¢cant decrease of ela¢n promoter activity in human keratinocytes of about 75%. Further deletion of promoter sequences down to 170 bp 5 0 of the translation start site (pSPL170) resulted in a decrease of promoter activity down to 10%. Transfection clone pSPL130, containing only minimal promoter consensus binding sequences showed almost no promoter activity in keratinocytes. Clone pSPL1000rev, in which the upstream sequence of the ela¢n gene is cloned in reverse orientation, resulted in a luciferase activity comparable with the empty luciferase gene vector pSLA4. Figure 2B depicts the activity of the promoter constructs transfected in keratinocytes that were subsequently stimulated with FBS (KGM/FBS), which is known to induce expression of the endogenous ela¢n gene . When the transfected cells were induced to di¡erentiate by growth factor depletion of growth factors and hydrocortisone, under which condition the endogenous ela¢n gene is virtually silent compared with FBS stimulation, the promoter constructs were still highly active (Fig 2B) . This discrepancy between the activity of the naked plasmid DNA and the activity of the chromatin-embedded endogenous gene suggest additional regulatory mechanisms for expression of the endogenous gene, as will be discussed below.
The ela¢n promoter confers keratinocyte-speci¢c gene expression To investigate whether the promoter region that was investigated here could confer cell-type speci¢c expression, reporter constructs were transfected in the epithelial A431 cell line, primary human skin ¢broblasts, and the U138-MG glioblastoma cell line. Figure 4 shows the relative activity of the transfection clone pSPL1000 in the di¡erent cell types, compared with the relative activity of the empty luciferase gene vector pSLA4. As can be seen in Fig 4, the ela¢n promoter was highly active in keratinocytes, whereas in ¢broblasts, glioblastoma cells, and A431 cells hardly any transcriptional activity was found. This e¡ect was also observed with other promoter constructs (data not shown).
Regulation of stably transfected ela¢n promoter constructs in HaCaT cells As described above, we observed a discrepancy between the transcriptional regulation by the endogenous ela¢n promoter and the regulation by promoter gene sequences that were plasmid encoded. In order to gain insight in the regulatory mechanism underlying this divergence, we performed . Ela¢n promoter activity in di¡erent cell types. Primary human keratinocytes, U138-MG glioblastoma cells, primary human skin ¢broblasts, and epithelial A431 cells were cotransfected with either empty reporter construct pSLA4 and EF2-bGAL or with transfection clone pSPL1000 and EF2-bGAL. Twenty-four hours after transfection cell cultures received fresh medium containing either 10%FCS (glioblastoma, ¢-broblast, epithelial A431) or 5%FCS (keratinocyte). After a ¢nal incubation of 24 h, cells were harvested and assayed for luciferase enzyme activity. Values represent the promoter activity of pSPL1000 compared to that of pSLA4 (assigned a value of 1). experiments using two di¡erent stably transfected HaCaT cell lines harboring either a 0.8 kb or a 4 kb ela¢n promoter region, which drives the transcription of an ela¢n^EGFP gene fusion. The reason that in these constructs we used EGFP as a reporter gene instead of luciferase is because these clones were generated in a separate study to be used in a £uorescence-based highthroughput screening system (Pol et al, 2002b) . Northern blot analysis using a probe directed against ela¢n demonstrated a TNF-a dependent induction of both the endogenous ela¢n mRNA and the ela¢n^EGFP speci¢c mRNA in either of the clones (Fig 5) . Note that discrepancies between basal transcription levels of ela¢n among di¡erent clones derived from the HaCaT cell line are a commonly observed phenomenon (as discussed below). The ela¢n^EGFP transcript was not detected in unstimulated cultures of these clones. In addition, by using an EGFP-speci¢c probe we con¢rmed that the ela¢n^EGFP mRNA is only present in the TNF-astimulated cultures (results not shown). These results indicate that the transgene is subjected to similar regulation as the endogenous gene, following cell stimulation with TNF-a. To investigate if the promoter construct contained all the necessary information to respond to a pharmacologic modulator of ela¢n expression, we used RA, a known inhibitor of ela¢n gene expression (Nagpal et al, 1996; Lee et al, 1998) Addition of RA in the dose range of 10 À6 , 10
À7
, and 10 À8 M caused a concentrationdependent decrease of endogenous ela¢n mRNA in both unstimulated and TNF-a stimulated cultures. We found that RA had no e¡ect on transcriptional regulation of ela¢n^EGFP as witnessed by the mRNA levels, which remained unchanged for all RA concentrations tested (see Fig 5) . These observations were con¢rmed at the protein level by data from two different enzyme-linked immunosorbent assays, one speci¢c for endogenous ela¢n protein and the other one speci¢c for the fusion protein transcribed from the transgene. Figure 6 , parts (A) and (B), show, respectively, the concentrations of endogenous ela¢n and the relative levels of ela¢n^EGFP fusion protein in culture medium of TNF-a stimulated cultures of the 0.8 kb ela¢nprom clone. It was found that levels of ela¢n decreased in a concentration-dependent way by increasing levels of RA, whereas no e¡ect of RA was observed on the level of ela¢n^EGFP fusion protein in culture medium.
DISCUSSION
Previous studies on the ela¢n promoter in other cell types have provisionally assigned the transcription start site on the basis of the location of a putative TATA box at position^94/^89 (all positions mentioned here are relative to the translation start site). Here we have experimentally determined the transcription start site of the ela¢n gene using two independent methods. We found that transcription starts at a point di¡erent than was expected, resulting in an mRNA with an unusually short 5 0 -UTR. This would imply that the presumed TATA box is located further away from the transcription start site than the canonical 25 bp. In view of these results we suggest that the TATA box sequence at position À94/À89 could be nonfunctional. Alternatively, at position À48/ À42 we found a sequence TAAAGAT, that is, with respect to spacing, more likely to serve as the actual TATA box. The fact that this proposed TATA box deviates from the consensus sequence for TATA boxes (TATA[A/T]A[A/T]) might explain the existence of multiple transcription start points (Smale and Baltimore, 1989) .
A previous study by others, using ela¢n promoter constructs in a mammary epithelial cell line, has suggested the importance of an alkaline phosphatase-1 site at^545/^539 (Zhang et al, 1997) . This was, however, not evident in our study as we found no decrease of promoter activity upon deletion of a sequence region Figure 5 . E¡ect of TNFa and RA on the mRNA expression of ela¢n and ela¢n-EGFP in cell cultures of stably transfected HaCaT cell lines. Both unstipulated and TNFa-stimulated (25 ng/ml) cultures of the 0.8 kb-and the 4 kb-ela¢nprom clone were treated with indicated amounts of RA for 72 h. Northern blot analysis was performed on total RNA isolated from these cultures. Samples were hybridized using a probe directed against ela¢n. from À1021 to À440.We found a signi¢cant decrease of promoter activity upon deletion of the sequence from À440 to À290. This region contains three NF-IL6 consensus binding sequences; however, the importance of this region has not been demonstrated in promoter constructs described by others using epithelial cell lines from other organs. This indicates that expression regulation of plasmid-encoded reporter constructs can vary between cell types from di¡erent tissues, or between primary cells (used by us) and cell lines. Further reduction of the ela¢n promoter region between À170 and À130 virtually abolished all residual promoter activity. In this region of the ela¢n promoter a consensus sequence for the transcription factor NFkB is present at À163 to À154. The importance of this site has been established before in transient transfection assays in a lung epithelial cell line (Bingle et al, 2001 ).We have not further investigated the functional significance of the NFkB site by internal mutation of this site in a larger fragment.
Our transfection experiments with ela¢n promoter constructs in keratinocytes showed a discrepancy between the expression of these clones and the endogenous gene. Whereas the endogenous ela¢n gene is induced in cultured keratinocytes by the addition of 5% FBS, the reporter gene constructs are active under all culture conditions. We therefore surmised that the reporter constructs consisting of naked plasmid DNA were not suitable to study ela¢n gene regulation in further detail. Using stably transfected reporter constructs in the HaCaT keratinocyte cell line we could indeed demonstrate that both a 0.8 kb and a 4 kb promoter fragment contained enough information for TNF-a induction of the transgene. The discrepancy between transcription of naked DNA from promoter constructs and the nuclear DNA wrapped in a highly organized chromatin structure has been observed frequently (DiSepio et al, 1995; Felsenfeld et al, 1996) . Therefore, also other processes such as silencing elements not present in the transfection clones, mRNA stability or higher order chromatin structure might be involved in transcription regulation of the endogenous ela¢n gene. In that respect p38 kinase activity, which is crucial for ela¢n expression in vitro, could play a part. Recently it has been described in a number of papers that mRNA can be stabilized through mitogen-activated protein kinase mediated processes, including p38 (Chen et al, 1998; Dean et al, 1999) , upon cellular stress. With respect to mRNA stability the unusual length of the 5 0 -untranslated region of the ela¢n mRNA could be of some signi¢cance, although it has been described that the 3 0 -UTR rather than the 5 0 -UTR is important for mRNA stability (Wickens et al, 1997; Day and Tuite, 1998) .
With respect to basal transcription levels of endogenous ela¢n (Fig 3) , it should be noted that these levels are not identical between stably transfected clones tested. This can be explained by the fact that the parental HaCaT cell line is indeed a line and not a clone. Originally, this line was karyotyped as being aneuploid (Boukamp et al, 1988) . We have con¢rmed this aneuploidity and have also found the HaCaT cell line to be heterogeneous with respect to chromosome number. It is from this cell line that we obtained single cells of which clones were derived. These now can have distinct transcription levels of endogenous ela¢n because they originate from di¡erent cells.
The rationale to study regulation of ela¢n expression was based on the assumption that ela¢n is a model gene for the activated keratinocyte pathway. We reasoned that elucidation of ela¢n induction, regulation of its expression, and pharmacologic manipulation could lead to further insight into the various epidermal di¡erentiation pathways or could even shed light on keratinocyte abnormalities, e.g., as observed in psoriasis. Having established that chromosomal integration of the ela¢n promoter/ reporter construct was necessary for proper regulation, we asked if these cell lines could be used to study the e¡ect of pharmacologic manipulation of ela¢n expression. Unfortunately, we found that the expression of the stably transfected reporter constructs carrying a 0.8 kb or a 4 kb ela¢n promoter fragment are not subjected to RA-induced suppression as is the case for the endogenous gene. This strongly suggests that additional cisacting sequences or a correct genomic environment is required. In conclusion, the results presented in this study show the complex regulation of the ela¢n gene and provide the basis for further studies needed to unravel this gene's molecular regulation mechanism.
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